Hulett Tyler W, Fox Bernard A, Messenheimer David J, Marwitz Sebastian, Moudgil Tarsem, Afentoulis Michael E, Wegman Keith W, Ballesteros-Merino Carmen, Jensen Shawn M
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA.
Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Providence Portland Medical Center, Portland, OR, USA; Oregon Health & Science University, Portland, OR, USA; UbiVac, Portland, OR, USA.
Surg Oncol Clin N Am. 2019 Jul;28(3):505-518. doi: 10.1016/j.soc.2019.02.006. Epub 2019 Apr 12.
In our opinion the most urgent needs to improve patient outcomes are: 1) a deeper ability to measure cancer immunobiology, and 2) increased availability of agents that, coupled with predictive biomarkers, will be used to tailor anti-cancer immunity. Tailoring effective immunotherapy will entail combinations of immunotherapeutics that augment priming of anti-cancer immunity, boost expansion of effector and memory cells of the T, B and NK lineage, amplify innate immunity and relieve checkpoint inhibition. Alternatives to inducing adaptive immunity to cancer include synthetic immunology that incorporate bi-specifics that target T cells to cancer or adoptive immunotherapy with gene-modified immune cells.
我们认为，改善患者治疗效果的最迫切需求是：1）更深入地测量癌症免疫生物学的能力，以及2）增加与预测性生物标志物相结合用于定制抗癌免疫的药物的可及性。定制有效的免疫疗法需要多种免疫治疗药物的联合使用，这些药物可增强抗癌免疫的启动，促进T、B和NK谱系效应细胞和记忆细胞的扩增，增强先天免疫并解除检查点抑制。诱导针对癌症的适应性免疫的替代方法包括合成免疫学，即采用靶向T细胞与癌症的双特异性抗体，或采用基因修饰免疫细胞的过继性免疫疗法。
